Company Organon & Co.

Company Organon & Co.

OGN

US68622V1061

Pharmaceuticals

Analysts' Consensus

Equities

OGN

US68622V1061

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Group companies

Sector

Sales per Business

Sales per region

Ratings for Organon & Co.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Group companies

Sector

Sales per Business

Sales per region

Ratings for Organon & Co.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Nyse Other stock markets 01:30:02 27/04/2024 am IST			5-day change	1st Jan Change
18.55 ^USD	+0.71%		+4.10%	+28.64%

09/04	Morgan Stanley Lifts Price Target on Organon to $18 From $17, Keeps Equalweight Rating	MT
08/04	Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint	MT

Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. The Companyâs Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.

Number of employees: 10,000

USD in Million	2022	Weight	2023	Weight	Delta
Women's Health - Nexplanon/Implanon NXT 13.3 %	834	13.5 %	830	13.3 %	-0.48%
Cardiovascular - Atozet 8.3 %	457	7.4 %	519	8.3 %	+13.57%
Respiratory - Singulair 6.5 %	411	6.7 %	404	6.5 %	-1.70%
Other - Other 5.1 %	326	5.3 %	319	5.1 %	-2.15%
Cardiovascular - Zetia 4.9 %	357	5.8 %	306	4.9 %	-14.29%
Cardiovascular - Cozaar/Hyzaar 4.5 %	323	5.2 %	281	4.5 %	-13.00%
Biosimilars - Renflexis 4.4 %	226	3.7 %	278	4.4 %	+23.01%
Other Non-opioid Pain, Bone and Dermatology 4.4 %	273	4.4 %	275	4.4 %	+0.73%
Women's Health - Follistim AQ 4.2 %	229	3.7 %	262	4.2 %	+14.41%
Non-opioid Pain, Bone and Dermatology - Arcoxia 4.1 %	241	3.9 %	257	4.1 %	+6.64%
Respiratory - Nasonex 4.0 %	238	3.9 %	253	4.0 %	+6.30%
Respiratory - Dulera 3.1 %	180	2.9 %	194	3.1 %	+7.78%
Other Women's Health 2.7 %	204	3.3 %	171	2.7 %	-16.18%
Non-opioid Pain, Bone and Dermatology - Fosamax 2.5 %	152	2.5 %	159	2.5 %	+4.61%
Biosimilars - Ontruzant 2.5 %	122	2.0 %	155	2.5 %	+27.05%
Other Cardiovascular 2.5 %	159	2.6 %	155	2.5 %	-2.52%
Women's Health - NuvaRing 2.4 %	173	2.8 %	152	2.4 %	-12.14%
Respiratory - Clarinex 2.2 %	125	2.0 %	136	2.2 %	+8.80%
Women's Health - Marvelon/Mercilon 2.1 %	110	1.8 %	134	2.1 %	+21.82%
Cardiovascular - Vytorin 2.1 %	130	2.1 %	129	2.1 %	-0.77%
Other - Propecia 2.0 %	125	2.0 %	125	2.0 %	0.00%
Other 1.9 %	146	2.4 %	121	1.9 %	-17.12%
Women's Health - Ganirelix Acetate Injection 1.8 %	123	2.0 %	110	1.8 %	-10.57%
Other - Proscar 1.5 %	101	1.6 %	97	1.5 %	-3.96%
Non-opioid Pain, Bone and Dermatology - Diprospan 1.5 %	122	2.0 %	91	1.5 %	-25.41%
Other Respiratory 1.2 %	83	1.3 %	77	1.2 %	-7.23%
Biosimilars - Brenzys 1.2 %	75	1.2 %	73	1.2 %	-2.67%
Cardiovascular - Rosuzet 1.1 %	71	1.1 %	70	1.1 %	-1.41%
Biosimilars - Hadlima 0.7 %	19	0.3 %	44	0.7 %	+131.58%
Women's Health - Jada 0.7 %	-	-	43	0.7 %	-
Biosimilars - Aybintio 0.7 %	39	0.6 %	43	0.7 %	+10.26%

USD in Million	2022	Weight	2023	Weight	Delta
Europe and Canada 26.7 %	1,631	26.4 %	1,673	26.7 %	+2.58%
United States 23.6 %	1,437	23.3 %	1,478	23.6 %	+2.85%
Asia Pacific and Japan 18.0 %	1,143	18.5 %	1,129	18.0 %	-1.22%
Latin America, Middle East, Russia and Africa 15.4 %	895	14.5 %	965	15.4 %	+7.82%
China 13.8 %	917	14.9 %	864	13.8 %	-5.78%
Global 2.5 %	151	2.4 %	154	2.5 %	+1.99%

Managers	Title	Age	Since
Kevin Ali CEO	Chief Executive Officer	63	02/21/02
Matthew Walsh DFI	Director of Finance/CFO	57	02/21/02
Juan Camilo Arjona Ferreira CTO	Chief Tech/Sci/R&D Officer	54	05/23/05
Rachel Stahler CTO	Chief Tech/Sci/R&D Officer	48	01/21/01
Marcel van Duin CTO	Chief Tech/Sci/R&D Officer	-	01/22/01
Jennifer Halchak IRC	Investor Relations Contact	-	-
Charlotte Owens PRN	Corporate Officer/Principal	-	05/23/05
Kirke Weaver LAW	General Counsel	-	01/22/01
Vittorio Nisita PRN	Corporate Officer/Principal	56	02/21/02
Joseph Morrissey PRN	Corporate Officer/Principal	59	02/21/02

Members of the board	Title	Age	Since
Rochelle Lazarus BRD	Director/Board Member	76	02/21/02
Carrie Cox CHM	Chairman	66	02/21/02
Robert Essner BRD	Director/Board Member	76	02/21/02
Helene Gayle BRD	Director/Board Member	69	02/21/02
Shalini Sharp BRD	Director/Board Member	49	02/21/02
R. Alan B. Ezekowitz BRD	Director/Board Member	70	02/21/02
Philip Ozuah BRD	Director/Board Member	61	02/21/02
Grace Whiteford BRD	Director/Board Member	61	02/21/02
Ma. Fatima Francisco BRD	Director/Board Member	55	02/21/02
Kevin Ali CEO	Chief Executive Officer	63	02/21/02

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	255,638,256	255,270,098 ( 99.86 %)	0	99.86 %

Name	Equities	%	Valuation
BlackRock Advisors LLC 12.69 %	32,436,117	12.69 %	610 M $
Vanguard Fiduciary Trust Co. 11.97 %	30,597,237	11.97 %	575 M $
Massachusetts Financial Services Co. 3.994 %	10,211,008	3.994 %	192 M $
STATE STREET CORPORATION 3.694 %	9,442,763	3.694 %	178 M $
Eaton Vance Management 2.292 %	5,859,028	2.292 %	110 M $
Sound Shore Management, Inc. 1.829 %	4,675,137	1.829 %	88 M $
Citadel Securities GP LLC 1.647 %	4,210,096	1.647 %	79 M $
BNY Mellon Investment Adviser, Inc. 1.563 %	3,996,455	1.563 %	75 M $
Geode Capital Management LLC 1.527 %	3,904,165	1.527 %	73 M $
Slate Path Capital LP 1.401 %	3,580,786	1.401 %	67 M $

Organon & Co.

30 Hudson Street 33rd floor

07302, Jersey City

+551 430 6900

http://www.organon.com

Name	Category and Sector
FULFORD (INDIA) LIMITED	Pharmaceuticals: Major
Organon (India) Pvt Ltd. Organon (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology Organon India Pvt Ltd. manufactures and distribution of pharmaceutical preparations. The company is headquartered in Mumbai, India.	Pharmaceuticals: Major
Dashtag Dashtag Financial ConglomeratesFinance Founded in 1906, Dashtag is a part of Organon & Co. and operates an investment holding British company. The private company is based in Hoddesdon, UK.	Financial Conglomerates
GTS FI BV GTS FI BV Financial ConglomeratesFinance Part of Organon & Co., GTS FI BV is an investment holding Dutch company that provides financing services. The private company is located in Netherlands.	Financial Conglomerates
Organon Finance 1 LLC	Finance/Rental/Leasing
Organon LLC
Organon Foreign Debt Co-Issuer BV

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

18.55 USD

Average target price

21.5 USD

Spread / Average Target

+15.90%

Consensus

Estimates Revisions

Company calendar

	1st Jan change	Capi.
ORGANON & CO.	+28.64%	4.77B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals